If BPC-157 is the peptide community's go-to for targeted healing, TB-500 is its systemic counterpart. Where BPC-157 concentrates its repair activity at or near injury sites, TB-500 travels through the entire body, promoting tissue repair, reducing inflammation, and supporting healing processes at a systemic level. The two peptides are so frequently discussed together that their combination has earned its own name: the Wolverine Stack, a reference to the Marvel character's legendary healing ability.
TB-500 has an unusual research history. Some of the most extensive data on its healing properties comes not from human medicine but from the equine industry, where Thymosin Beta-4 products have been used for decades in racehorses to support recovery from injuries and accelerate recovery. This creates an evidence base that is substantial in volume but unconventional in its sources, and understanding what the research actually shows requires sorting through animal models, horse racing data, and limited human evidence.
This guide covers the science behind TB-500, the state of the research, how it compares to BPC-157, the current legal landscape, and what you need to know about safety. We do not provide dosing information. TB-500 therapy, when it becomes legally available, should be pursued only under physician supervision.
What is TB-500?
TB-500 is a synthetic peptide that replicates the active region of Thymosin Beta-4 (Tβ4), a naturally occurring protein found in virtually all human and animal cells. Thymosin Beta-4 is a 43-amino-acid protein that was first isolated from the thymus gland in the 1960s as part of research into thymic hormones and their role in immune function. It was later discovered that Thymosin Beta-4 is far more than an immune peptide: it is one of the body's primary mediators of tissue repair, wound healing, and cellular migration.
The name “TB-500” is technically a product designation rather than a scientific name. It refers to a synthetic version of Thymosin Beta-4 that reproduces the key functional region of the protein, specifically the actin-binding domain centered around the amino acid sequence Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys (LKKTETQ). This sequence is the portion of Thymosin Beta-4 that is responsible for its most important biological activities: actin binding, cell migration promotion, and anti-inflammatory signaling. In practice, the terms TB-500 and Thymosin Beta-4 are often used interchangeably in the peptide community, though they are technically not identical molecules.
Thymosin Beta-4 is found at high concentrations in wound fluid, blood platelets, and other tissues involved in healing and repair. When tissue damage occurs, local concentrations of Thymosin Beta-4 increase dramatically, serving as a signal that mobilizes the body's repair processes. The synthetic version, TB-500, is designed to amplify this natural healing signal by providing additional Thymosin Beta-4 activity above what the body produces on its own.
Unlike many peptides in the optimization space that are entirely synthetic constructs, TB-500 is replicating a protein that your body already produces and uses every day for tissue maintenance and repair. The therapeutic concept is straightforward: by supplementing the body's natural Thymosin Beta-4, you support and amplify the healing processes that are already occurring. This is analogous to how Sermorelin amplifies natural growth hormone production rather than replacing it, a theme that runs through much of peptide therapy.
How TB-500 works
TB-500's mechanism of action is centered on its interaction with actin, a protein that forms the structural scaffolding of cells and is critical for cell movement, shape, and division. Understanding actin's role is essential to understanding why TB-500 has such broad healing effects.
Actin regulation.Actin is one of the most abundant proteins in human cells. It forms filaments that provide structural support, enable cell movement, and participate in cell division. Thymosin Beta-4 is the primary regulator of the actin pool in cells: it sequesters actin monomers (individual actin units) and controls their availability for filament assembly. By upregulating actin organization, TB-500 enhances cells' ability to move, divide, and build the structural framework needed for tissue repair. This is a foundational mechanism that affects virtually every tissue type in the body.
Cell migration.When tissue is damaged, repair cells need to migrate to the injury site. This migration depends on cells being able to extend projections, attach to surrounding matrix, pull themselves forward, and detach from behind, a process called chemotaxis that is fundamentally dependent on actin dynamics. TB-500 promotes cell migration by optimizing the actin machinery that drives this movement. Unlike BPC-157, which promotes healing primarily through local mechanisms like angiogenesis and fibroblast stimulation at the injury site, TB-500 enhances the body's ability to send repair cells to injury sites from distant locations. This systemic mobilization of repair resources is what gives TB-500 its whole-body healing character.
Angiogenesis.Like BPC-157, TB-500 promotes the formation of new blood vessels. Research has demonstrated that Thymosin Beta-4 is a potent angiogenic factor, stimulating endothelial cell migration and the formation of new capillary networks. New blood vessel formation is critical for tissue repair because healing tissues require increased blood supply to deliver oxygen, nutrients, and immune cells. TB-500's angiogenic activity complements its cell migration effects: it both mobilizes repair cells and builds the vascular infrastructure to support them.
Anti-inflammatory activity. TB-500 reduces inflammation through multiple pathways. It downregulates pro-inflammatory cytokines, reduces the activity of inflammatory signaling cascades, and promotes the resolution of inflammation rather than simply suppressing it. This anti-inflammatory activity is systemic rather than local, meaning TB-500 can reduce inflammatory burden throughout the body rather than just at a single site. This systemic anti-inflammatory effect is particularly relevant for conditions involving chronic, widespread inflammation.
Cardiac protection. One of the most studied aspects of Thymosin Beta-4 is its protective effect on cardiac tissue. Research has shown that Thymosin Beta-4 can activate cardiac progenitor cells (resident stem cells in the heart), promote the survival of cardiomyocytes (heart muscle cells) after ischemic injury, and reduce scar formation following heart attack. These cardiac effects have been the focus of some of the most rigorous research on Thymosin Beta-4, including studies that have advanced toward clinical trials in humans.
The net result of these mechanisms is a compound that promotes healing at a systemic level. TB-500 does not just accelerate repair at one specific injury site. It enhances the body's overall capacity to detect damage, mobilize repair resources, build new blood supply, reduce inflammatory barriers to healing, and rebuild tissue. This systemic character is what distinguishes it from more locally-acting healing compounds like BPC-157 and is why the two are so often used together.
Research and evidence
The evidence base for TB-500 is substantial but distributed across unusual sources. Understanding the research landscape requires looking at preclinical studies, cardiac research, equine data, and the limited human evidence separately.
Wound healing and tissue repair
The foundational research on Thymosin Beta-4 involves wound healing. Multiple animal studies have demonstrated that Thymosin Beta-4 accelerates wound closure, reduces scar formation, and improves the quality of healed tissue. In rodent models, topical and systemic administration of Thymosin Beta-4 resulted in faster epithelial closure, enhanced collagen deposition, and improved tensile strength of healed wounds. These effects are consistent across different wound types including incisional wounds, burns, and chronic wounds.
The wound healing research has advanced further than most other Thymosin Beta-4 applications. RegeneRx Biopharmaceuticals developed a topical Thymosin Beta-4 product (RGN-137) that completed multiple clinical trials for chronic wound healing, including diabetic and venous stasis ulcers. While the commercial development pathway has been complex, the clinical data from these trials represents some of the only human evidence for Thymosin Beta-4's healing properties.
Cardiac tissue repair
The cardiac research on Thymosin Beta-4 is among the most rigorous and promising in the field. Studies published in leading journals including Nature and the Journal of the American Heart Association have demonstrated that Thymosin Beta-4 can activate epicardium-derived progenitor cells in the heart, promoting the regeneration of cardiac tissue after myocardial infarction (heart attack). This is significant because the adult heart has very limited regenerative capacity, and the ability to activate resident cardiac progenitor cells could represent a paradigm shift in treating heart disease.
Research has shown that Thymosin Beta-4 administration after experimentally induced heart attacks in mice reduces infarct size, improves cardiac function, and promotes the formation of new cardiomyocytes from progenitor cells. The mechanism involves Thymosin Beta-4 reactivating developmental programs in adult cardiac cells that are normally dormant, essentially reminding the heart how to repair itself using tools it possessed during embryonic development but lost in adulthood.
These cardiac findings have generated significant interest in the cardiology research community and represent one of the strongest lines of evidence for Thymosin Beta-4's therapeutic potential.
Hair regrowth
An intriguing line of research has demonstrated that Thymosin Beta-4 promotes hair growth in animal models. Studies have shown that Thymosin Beta-4 activates hair follicle stem cells, stimulating the transition from the resting phase (telogen) to the active growth phase (anagen) of the hair cycle. In mouse models, Thymosin Beta-4 treatment accelerated hair regrowth following shaving and promoted the development of new hair follicles. The mechanism appears to involve Thymosin Beta-4's effects on stem cell activation and cell migration, applied specifically to the hair follicle niche.
Anecdotal reports from human TB-500 users have occasionally described improvements in hair quality and thickness, though systematic evaluation of hair effects in humans has not been conducted. This remains a preclinical finding with suggestive but unproven relevance to human hair loss.
Nervous system repair
Research has demonstrated neuroprotective and neuroregenerative effects of Thymosin Beta-4. In animal models of traumatic brain injury and spinal cord injury, Thymosin Beta-4 administration improved functional recovery, reduced inflammation in neural tissue, and promoted the survival and regeneration of neurons and oligodendrocytes (the cells that produce the myelin sheath insulating nerve fibers). These findings are consistent with Thymosin Beta-4's general mechanism of promoting cell migration and reducing inflammation, applied to the nervous system context.
Equine research
TB-500 has an extensive history of use in the equine industry, particularly in racehorse rehabilitation. Thymosin Beta-4 products have been used for years to treat tendon and ligament injuries in horses, accelerate recovery from training stress, and support overall musculoskeletal health. The equine data is valuable because horses are large animals with musculoskeletal systems that share meaningful similarities with humans, and the injuries treated (tendon strains, ligament tears, joint inflammation) are directly relevant to human conditions. However, it is important to note that the equine use of Thymosin Beta-4 has also been controversial in racing, with some jurisdictions banning its use in competition due to its performance-enhancing potential.
TB-500 vs BPC-157
TB-500 and BPC-157 are the two most discussed healing peptides, and understanding their differences is essential for anyone considering either compound. They are complementary rather than competitive, working through different mechanisms and exhibiting different patterns of activity.
| Characteristic | TB-500 | BPC-157 |
|---|---|---|
| Origin | Thymosin Beta-4 (thymus gland protein) | Body Protection Compound (gastric protein) |
| Primary action | Systemic healing throughout the body | Local healing at or near injury site |
| Key mechanism | Actin regulation, cell migration | Angiogenesis, fibroblast stimulation |
| Anti-inflammatory | Systemic, whole-body | Primarily local, at injury site |
| GI healing | Limited evidence | Strong evidence, derived from gastric protein |
| Cardiac effects | Strong evidence for cardiac tissue repair | Limited cardiac-specific research |
| Legal status (2026) | Category 2 (pending reclassification) | Category 2 (pending reclassification) |
The most important takeaway from this comparison is that TB-500 and BPC-157 are not substitutes for each other. They address tissue repair through fundamentally different mechanisms: BPC-157 creates a favorable healing environment at the local level through angiogenesis and growth factor modulation, while TB-500 mobilizes the body's repair resources at a systemic level through actin regulation and cell migration enhancement.
This is why they are so commonly combined in the “Wolverine Stack.” The combination addresses healing from both angles simultaneously: BPC-157 handles targeted local repair while TB-500 provides broad systemic support. Many practitioners and users report that the combination produces results exceeding what either peptide achieves individually, though formal comparative studies have not been conducted.
For a comprehensive look at BPC-157, including its mechanisms, research, and legal status, see our detailed guide: BPC-157: Research, Benefits, and Legal Status.
Legal status
TB-500 is currently classified as a Category 2 peptide in the United States. This means it cannot be legally compounded by licensed pharmacies or prescribed by physicians through standard compounding channels. It is not a controlled substance, so possession is not criminal, but selling it for human use without proper authorization is illegal.
TB-500 is among the peptides that are expected to be reclassified to Category 1 status under the ongoing regulatory review process. The February 2026 announcements regarding peptide reclassification included Thymosin Beta-4 among the compounds under review for restored access. Category 1 designation would allow licensed compounding pharmacies to produce TB-500 and physicians to prescribe it to patients through legitimate medical channels.
The timeline for reclassification remains uncertain. While the political and regulatory momentum favors restoring access to healing peptides like TB-500, the formal FDA process involves evaluation, documentation, and publication steps that take time. Patients who are interested in TB-500 therapy should prepare by establishing a relationship with a physician who is knowledgeable about peptide therapy, rather than seeking grey-market alternatives that carry risks of contamination, incorrect potency, and legal exposure.
For a comprehensive overview of the Category 1 and Category 2 system, the reclassification process, and the broader legal framework for peptides, see our complete guide: Are Peptides Legal? 2026 Guide.
Safety profile
Evaluating TB-500's safety requires acknowledging the significant limitations of the available data. Unlike Sermorelin, which has FDA approval history and decades of clinical use, or even BPC-157, which has an extensive preclinical literature, TB-500's safety profile is built on a narrower evidence base.
What we know. Thymosin Beta-4 is a naturally occurring protein found in virtually all human cells. It is present at high concentrations in blood platelets, wound fluid, and developing tissues. The fact that it is a normal component of human physiology provides some baseline reassurance about its safety, though supplementing a natural protein at supraphysiological levels introduces considerations that do not apply to its endogenous role. In animal studies, Thymosin Beta-4 has been administered at various levels without producing significant toxicity. The topical Thymosin Beta-4 product (RGN-137) that underwent clinical trials demonstrated acceptable safety in human subjects. Anecdotal reports from the peptide community rarely describe serious adverse effects from TB-500 use.
Common reported effects. Anecdotal reports from human users most commonly describe mild and transient effects including temporary lethargy or fatigue (particularly after initial administrations), head rush or lightheadedness, and mild headache. These effects are generally self-limiting and do not persist with continued use.
The angiogenesis concern. Like BPC-157, TB-500 promotes new blood vessel formation. This is beneficial for tissue repair but introduces a theoretical concern in the context of cancer. Tumor growth depends on angiogenesis to establish blood supply for the growing malignancy. While there is no published evidence that TB-500 promotes tumor growth, and Thymosin Beta-4 research has not identified it as a tumor promoter, the theoretical possibility has not been definitively ruled out through long-term studies. This concern is not unique to TB-500; it applies to any compound that promotes angiogenesis, including BPC-157 and even exercise (which is a potent angiogenic stimulus). Physician evaluation, including appropriate cancer screening, should precede any peptide therapy that involves angiogenic compounds.
Limited long-term human data. The most important limitation is the absence of long-term human safety data from controlled trials. Most of what we know about TB-500 safety in humans comes from short-term clinical trial data (wound healing studies), equine use, and anecdotal reports. These sources provide a generally reassuring picture, but they cannot substitute for the kind of systematic, long-term safety evaluation that comes from formal clinical development.
The bottom line on safety: TB-500 appears to be well-tolerated based on the available evidence, but that evidence is more limited than what exists for some other peptides in the healing category. Physician supervision is essential for evaluating individual risk factors, monitoring response, and adjusting therapy as needed. Individuals with a history of cancer or active malignancy should exercise particular caution and discuss the angiogenesis considerations with their physician.
Frequently asked questions
What is TB-500?
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring protein found in virtually all human cells. Thymosin Beta-4 plays a critical role in tissue repair, cell migration, and inflammation regulation. TB-500 reproduces the active region of this protein, amplifying the body's natural healing processes at a systemic level. It promotes repair throughout the body rather than acting at a single injury site, which distinguishes it from more locally-acting healing peptides like BPC-157. For a comprehensive overview of healing peptides and how they work, see our peptide therapy guide.
Is TB-500 legal?
TB-500 is currently classified as a Category 2 peptide in the United States. It cannot be legally compounded or prescribed through standard medical channels. It is not a controlled substance, so possession is not criminal, but selling it for human use is illegal. TB-500 is expected to be reclassified to Category 1 status, which would restore legal access through physician prescription and licensed compounding pharmacies. For the full legal picture, see Are Peptides Legal? 2026 Guide.
What is the difference between TB-500 and BPC-157?
TB-500 acts systemically throughout the body by upregulating actin and promoting cell migration to injury sites from distant locations. BPC-157 acts primarily locally, promoting angiogenesis and fibroblast activity at or near the injury site. They use different mechanisms and are commonly combined in the “Wolverine Stack” because their complementary effects address healing from both systemic and local perspectives. For details on BPC-157, see our BPC-157 guide. For information on peptides that support muscle growth and recovery, see our guide on the best peptides for muscle growth.
Is TB-500 safe?
TB-500 is generally well-tolerated based on animal studies, equine research, and anecdotal reports. No serious adverse effects have been consistently reported. Common anecdotal side effects are mild: temporary fatigue, headache, and lightheadedness. The main theoretical concern involves TB-500's promotion of angiogenesis, which could theoretically support tumor vascularization in individuals with existing malignancies. This has not been demonstrated in research but has not been ruled out. Long-term human safety data from controlled trials is limited. Physician supervision is essential.
Can TB-500 be used for hair regrowth?
Animal research has shown that Thymosin Beta-4 activates hair follicle stem cells and promotes the transition from resting to active growth phase, accelerating hair regrowth in mouse models. Some human users have anecdotally reported improvements in hair quality and thickness. However, no published human clinical trials have specifically evaluated TB-500 for hair loss. The evidence remains preclinical and anecdotal. TB-500 should not be considered a proven treatment for hair loss based on the current evidence.